Vaccinated children suffer severe disease after vaccination. Vaccine program now suspended by government
733,000 children were injected with this vaccine before it was suspended from use. Children suffered more cases of ‘severe disease’ following vaccination.
French pharmaceutical giant Sanofi announced December 2017, that its world-first dengue vaccine could lead to more severe symptoms for people who had not previously been infected.
The Philippines has vaccinated more than 733,000 children with Dengvaxia since 2016 when it became the first country to start using it on a mass scale. THREE hundred sixty two recipients of the dengue vaccine from the Department of Health (DOH) have experienced Adverse Event Following Immunization (AEFI).
But it said Friday the program had been suspended.
“In the light of this new analysis, the DOH (Department of Health) will place the dengue vaccination programme on hold while review and consultation is ongoing with experts, key stakeholders, and the WHO (World Health Organization),” Health Secretary Francisco Duque said.
Sanofi had initially said its Dengvaxia vaccine was “critical” in the fight against dengue, the world’s most common mosquito-borne virus.
“For those not previously infected by dengue virus, however, the analysis found that in the longer term, more cases of severe disease could occur following vaccination upon a subsequent dengue infection,” Sanofi said.
This is clinical evidence of extreme adverse reactions to the Dengue fever vaccine. While the vaccine is not used here in Idaho it begs the question, how much pre-licensing safety testing is done our vaccines prior to release and administration of our pediatric vaccines?
Bill and Melinda Gates fund fast track version of vaccine reported in 2011 http://www.who.int/bulletin/volumes/89/7/11-030711/en/
362 Adverse Reactions to fast tracked vaccine:
733,000 children injected with fast tracked vaccine prior to its suspension by government https://www.yahoo.com/news/philippines-suspends-world-first-dengue-vaccine-071338962.html
More information on this topic: